Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,295,646 for its "Smart Torquer" device, strengthening its intellectual property portfolio in nerve-sensing and modulation technology. The patent covers a device designed to enhance the manipulation of intravascular devices during minimally invasive procedures while enabling data communication.
The company's technology platform features a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. With over 80 issued patents and 40 pending applications, Autonomix is positioning itself in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases.
Positive
- Patent portfolio expanded with over 80 issued patents and 40 pending applications
- Technology addresses multi-billion-dollar market opportunity
- First-in-class technology platform with enhanced neural signal detection capabilities
- Potential applications across multiple high-value medical areas including cardiology, neurosurgery, and pain management
Negative
- None.
News Market Reaction – AMIX
On the day this news was published, AMIX gained 15.82%, reflecting a significant positive market reaction. Argus tracked a peak move of +48.6% during that session. Argus tracked a trough of -23.1% from its starting point during tracking. Our momentum scanner triggered 57 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $976K to the company's valuation, bringing the market cap to $7M at that time. Trading volume was exceptionally heavy at 8.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases
THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,295,646 (the ‘646 patent), titled, “Smart Torquer and Methods for Using the Same.” The newly issued ‘646 patent relates to a smart torquer device designed to enhance the manipulation of elongated intravascular devices during minimally invasive procedures, while integrating electronic components to facilitate both mechanical control and data communication.
“This patent strengthens our intellectual property portfolio and reinforces our commitment to developing differentiated technologies that address large and underserved markets. The smart torquer improves control and signal integration for intravascular procedures, which is essential for expanding our platform into high-growth areas like cardiology, neurosurgery, and interventional radiology. With the addition of this ‘646 patent to our over 80 issued patents, Autonomix is building a defensible position in a multi-billion-dollar opportunity where precision nerve-targeted interventions can reshape clinical outcomes,” commented Brad Hauser, CEO of Autonomix.
In particular, the ‘646 patent relates to, but is not limited to, an engaging mechanism that securely attaches to an intravascular device, a communication module that facilitates data exchange between systems, an electrical connection interface to transmit signals and a manipulator that allows the user to apply torque to the engaged device as it navigates the vascular system.
Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.
For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer and other indications and the ability of our patents to strengthen our strategic position. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
What is the new patent granted to Autonomix Medical (NASDAQ: AMIX)?
How many patents does Autonomix Medical (AMIX) currently hold?
What medical conditions can Autonomix Medical's (AMIX) technology potentially treat?
How does Autonomix Medical's (AMIX) nerve detection technology work?
What markets is Autonomix Medical (AMIX) targeting with its technology?
